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Abstract
Background: Resistance to extended-spectrum cephalosporins among Enterobacteriaceae has been reported yet
they serve as the last line treatment for severe infections in Uganda and other countries. This resistance often leads
to nosocomial infection outbreaks and therapeutic failures from multidrug resistant bacteria. The main objective of
this study was to determine the prevalence of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae
in clinical samples of patients in various wards of Mulago Hospital; Uganda’s main national referral and teaching hospital.
Methods: This cross-sectional study was conducted between January-April, 2014. Purposive consecutive sampling was
used to collect pus swab, urine, blood and CSF samples from patients in the various wards. A total of 245 consecutive,
non-repetitive, clinical samples were obtained and tested for phenotypic ESBL production using the Double Disc
Synergy Test using cefotaxime, ceftazidime, cefotaxime-clavulanic acid and ceftazidime-clavulanic acid.
Results: Results show that 47 % of the 245 samples had Enterobacteriaceae isolates. Of these isolates 62 % were ESBL
producers while 38 % were of non-ESBL phenotype. E. coli was the most isolated organism (53.9 %), followed by K.
pneumoniae (28.7 %). Majority of Enterobacteriaceae organisms were isolated from urine samples, followed by pus
samples and of these 64.9 % and 47.4 % were ESBL-producers respectively. Klebsiella pneumoniae had the highest
percentage of ESBL producers (72.7 %). There was a higher percentage of isolates showing resistance to ceftazidime
(73 %) compared to cefotaxime (57.5 %). All Enterobacter cloacae isolates showed resistance to ceftazidime. There
were no statistically significant association between phenotype (ESBL/non-ESBL) and patients’ age or gender or
Enterobacteriaceae spp.
Conclusions: This study reveals a high prevalence of ESBL producing organisms in Mulago Hospital and high levels of
resistance to third generation cephalosporins. In addition to undertaking appropriate infection control measures, there
is urgent need for formulation of an antibiotic policy in Uganda to prevent spread of these organisms. This also calls for
continuous monitoring and reporting of the presence of such organisms in order to ensure rational and judicious use
of antibiotics by clinicians.
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Background
Production of β-lactamase enzymes that hydrolyze the
β-lactam ring is a predominant resistance mechanism
for many Gram-negative bacteria including Enterobacte-
riaceae such as E. coli, Klebsiella pneumoniae, Klebsiella
oxytoca, Pseudomonas aeruginosa, Proteus mirabilis,
Enterobacter cloacae and Aeromonas spp. [1]. Extended-
Spectrum β-Lactamase (ESBL)-producing bacteria are cap-
able of expressing these enzymes and this confers bacterial
resistance to penicillins; first, second, and third-generation
cephalosporins and aztreonam. ESBL-producing bacteria
have been isolated in many parts of North America and
Europe [2] and in Africa. In one South African hospital, 36
% of K. pneumoniae isolates were ESBL-producers and
outbreaks of infections due to Klebsiella strains resistant to
third-generation cephalosporins have also been reported in
Nigeria and Kenya [3, 4]. In Uganda there has been lack of
published information about ESBL-producers among or-
ganisms isolated from patients.
ESBL producers have a wide clinical significance and
potential impact in healthcare settings especially in low
income countries such as Uganda. The selection pressure
and overuse of new antibiotics in the treatment of patients
leads to selection for new variants of β-lactamase pro-
ducers. ESBL producers are associated with various infec-
tions in virtually all body organs leading to meningitis,
pneumonia, urinary tract infections, septicaemia and
intra-abdominal infections [5, 6]. Other conditions include
osteomyelitis, endophthalmitis, pyomyositis and wound
infections [7].
The possible spread of ESBL-producing organisms in a
clinical setting is real. ESBL-associated antibiotic resist-
ance causes increased morbidity and mortality; and ham-
pers the control of infectious diseases. This in turn leads
to increase in durations of illness and hospital stay; in-
crease in health-care costs and more economic burden
to families. This study sought to determine the preva-
lence of ESBL-producing bacteria among isolates from
samples in various wards of Mulago Hospital, the main




This was a cross-sectional study conducted between
January-April 2014 to determine the prevalence of ESBL-
producing Enterobacteriaceae in clinical samples collected
from in-patient and out-patient wards of Mulago Hospital.
The samples collected included urine, swabs (oral, HVS,
wound), blood and CSF. Escherichia coli, Klebsiella pneu-
moniae, Proteus mirabilis and Enterobacter cloacae bac-
teria were isolated from the samples. The number of
samples containing ESBL-producing Enterobacteriaceae
was recorded. The prevalence of ESBL phenotypes among
the isolates was determined.
Sample size
The sample size was determined using the formula ad-
vanced by Kish and Leslie [8]. Basing on results of a previ-
ous study in a similar setting, a prevalence of 20 % [9] and
confidence interval of 95 % were used in the formula. The
sample size was estimated to be about 245 samples.
Sample collection and bacterial isolation
Samples from 25 wards of Mulago Hospital were asep-
tically collected by purposive consecutive sampling from
patients who gave informed written consent; properly
Table 2 Baseline characteristics of patients whose samples had Enterobacteriaceae isolates
ESBL n = 71 (61.7 %) Non-ESBL n = 44 (38.3 %) Total p value
Sex
Female 37 (52.1 %) 30 (68.2 %) 67 (58.3 %) 0.089
Male 34 (47.9 %) 14 (31.8 %) 48 (41.7 %)
Age Overall mean
Mean 42 (SD 22) 38 (SD 19) 40 0.355
The Chi-square and independent t-tests showed that sex and age were not significantly associated with ESBL phenotype
Chi-square and independent t-test
Table 1 Criteria for determining the potency of the test antibiotics
ESBLS E. coli ATCC 25922 K. pneumoniae ATCC 700603
Ceftazidime 30 μg (25-32 mm) (22-29 mm)
Cefotaxime 30 μg (29-35 mm) (18-22 mm)
The antibiotics had to show inhibition zone diameters in the above ranges in
order to be used in the study
Table 3 Enterobacteriaceae species isolated from patient samples
Isolates Frequency Percent
E. coli 62 53.9
Klebsiella pneumoniae 33 28.7
Proteus mirabilis 16 13.9
Enterobacter cloacae 4 3.5
Total 115 100.0
E. coli was the predominant isolate
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labelled and taken to the Microbiology Laboratory for
Enterobacteriaceae culture and isolation. The originating
ward, patient’s gender and age were recorded. The sam-
ples were inoculated by streaking on Blood agar (Oxoid,
UK), MacConkey agar (Oxoid, UK) and CLED agar (Oxoid,
UK) plates. The plates were incubated aerobically at
37 °C for 18–24 h to allow development of bacterial
colonies. Preliminary identification of the isolates was
done using phenotypic colonial characteristics. Con-
firmatory identification of the suspect colonies was car-
ried out by conventional biochemical tests as described
by Cheesbrough [10]. These were: indole, Methyl red,
Voges-Proskauer, citrate utilization and urease produc-
tion tests as well as triple sugar iron and oxidase tests.
Detection of ESBL-producing Enterobacteriaceae
ESBL detection was based on the Double Disc Synergy
Test and interpretation of the results done using the
CLSI M100-S20 (2010) [11]. Briefly; 3–5 colonies of each
isolate were picked from the growth plates with sterile
wire loop, and suspended in 1 ml of physiological saline.
The resultant bacterial suspension was matched to the
0.5 McFarland turbidity standard so as to approximate
the seeding density of the respective organisms. 100 μl the
bacterial suspension/broth culture were then surface-
spread on Muller Hinton Agar (Oxoid, UK) plates using a
sterile spreader. Antibiotic discs containing ceftazidime
(CTC), cefotaxime (CTZ), ceftazidime-clavulanic acid
(CFC) and cefotaxime-clavulanic acid (CTX) were placed
on the plates which were incubated overnight at 37 °C.
The zones of clearance (mm) for the respective antibiotics
were measured for each isolate using a divider and ruler.
Organisms were considered to be ESBL-producers if the
difference in zone of clearance between ceftazidime and
ceftazidime-clavulanic acid or cefotaxime and cefotaxime-
clavulanic acid was ≥5 mm. The prevalence of ESBL-
producing bacteria was determined using the formula:




Standard organisms (E. coli ATCC 25922 and K. pneu-
moniae ATCC 700603) were used to test for the potency
of the antimicrobial discs (Table 1).
Data analysis
Clinical and socio-demographic data were entered into
Epi InfoTM v7 and exported to SPSSv21. Pearson Chi-
square test was used to assess for any differences be-
tween the two ESBL phenotype categories with respect
to clinical and demographic parameters. The means of
the continuous variables, age and zones of clearance were
Fig. 1 Distribution of samples from the various wards. Surgical wards contributed the highest number of samples in the Microbiology laboratory
during the study period. Surgical wards – 1A, 2A, 2B, 2C, 3A, 5A, 5B, 5C and SOPD; Medical wards – 3B, 4A, 4B, 4C, 6A, 6B, MOPD, MAC, UCI-LTC
and UHI; Pediatric wards – 16A and 16C; General - OPD, MOPD, STD. Key: SOPD = Surgical Outpatients Dept; UCI-LTC = Uganda Cancer Institute-
Liquid Tumor Cancer, MAC =Medical assessment Centre; MOPD =Medical outpatients Dept; OPD = Outpatients Dept; STD = Sexually Transmitted
Diseases Dept; UHI = Uganda Heart Institute
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compared using the Independent t-test. Crude logistic re-
gression analysis was used to explore clinical and labora-
tory features of the ESBL phenotype for comparison with
non-ESBL Enterobacteriaceae phenotypes. The differences
were considered significant at p < 0.05.
Ethical considerations
The study protocol was approved by the Ethics Review
Committee of the School of Biomedical Sciences of Maker-
ere University Medical School. Permission was sought
from the hospital and laboratory authorities. The ethical
principles of scientific research as well as related national
laws and regulations were strictly adhered to.
Results
The mean age of the participants was 40 years as shown
in Table 2. Results indicated that 115 of the 245 samples
(47 %) had Enterobacteriaceae isolates. Of these isolates,
58.3 % were from female patients while 41.7 % were
from males (Table 2). Statistical analysis of patient data
using Chi-square and independent t-test indicated that
gender and age were not significantly associated with
ESBL phenotype. E. coli was the most isolated organism
(53.9 %, n = 62), followed by K. pneumoniae (28.7 %) as
shown in Table 3. Most samples with Enterobacteriaceae
isolates were from Obstetrics and Gynaecology wards i.e.
5A (10.4 %, n = 12) and 5C (11.3 %, n = 13) (Fig. 1).
Results further showed that 62 % of Enterobacteria-
ceae isolates were of the ESBL phenotype while 38 %
were of non-ESBL phenotype (Table 2). Most of the En-
terobacteriaceae were isolated from the urine samples
followed by pus samples as shown in Table 4 and Fig. 2.
However, just 64.9 % and 47.4 % of urine and pus isolates
respectively were ESBL-producers. On the other hand,
Table 4 Association between ESBL phenotype and
Enterobacteriaceae isolated, sample type and susceptibility pattern
ESBL (%) Non-ESBL (%) P value
Isolate
E. coli 36 (58.1) 26 (41.9) 0.924
Klebsiella pneumoniae 24 (72.7) 9 (27.3) 0.908
Enterobacter cloacae 1 (25) 3 (75) 0.695
Proteus mirabilis 10 (62.5) 6 (37.5) 0.999
Sample type
Urine 46 (63.9) 26 (36.1) 0.980
HVS 6 (54.5) 5 (45.5) 0.999
CSF 1 (100) 0 (0) 0.999
Urethral swab 1 (100) 0 (0) 1.000
Wound swab 2 (100) 0 (0) 1.000
Blood 2 (40) 3 (60) 1.000
Pus swab 9 (47.4) 10 (52.6) 0.999
Surgical wound swab 4 (100) 0 (0) 0.999
Ceftazidime Susceptibility
Resistant 62 (73.8) 22 (26.2) 0.408
Intermediate 4 (36.4) 7 (63.6) 0.187
Susceptible 5 (25) 15 (75) 0.480
Cefotaxime Susceptibility
Resistant 54 (81.8) 12 (18.2) 0.013
Intermediate 4 (30.8) 9 (69.2) 0.067
Susceptible 13 (36.1) 23 (63.9) 0.430
Binomial logistic regression
When analysed using binomial logistic regression, ESBL phenotype was
significantly associated with resistance to cefotaxime but not with resistance
to ceftadizime, bacterial species or sample type
Fig. 2 Distribution of Enterobacteriaceae-positive samples. Most of the Enterobacteriaceae were isolated from urine samples
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albeit their small number, all isolates from CSF, wound
and urethral swabs were ESBL producers (Fig. 2).
The mean zones of clearance for ESBL and non-ESBL
phenotypes were lowest for ceftazidime (10.1 ± 6.2 mm;
18.1 ± 7 mm respectively) and highest for cefotaxime-
clavulanic acid (25.1 ± 6.6 mm; 22.3 ± 8.3 mm respectively)
as shown in Table 5. The zones of clearance of ceftazidime
and cefotaxime were significantly associated with ESBL
phenotype (p = 0.000; 0.000 respectively) while those of
ceftazidime-clavulanic acid and cefotaxime-clavulanic acid
were not (p = 0.198, 0.051 respectively).
There was a higher percentage of isolates showing re-
sistance to ceftazidime (73 %) compared to cefotaxime
(57.5 %) as shown in Table 6. All Enterobacter cloacae
isolates were resistant to both cefotaxime and ceftazi-
dime. Table 4 shows that Klebsiella pneumoniae had the
highest percentage of ESBL producers (72.7 %). There were
no statistically significant association between phenotype
(ESBL/non-ESBL) and patients’ age or gender (Table 4).
Similarly, there were no significant association between
phenotype (ESBL/non-ESBL) and species of Enterobacteri-
aceae (E. coli, Klebsiella pneumoniae, Enterobacter cloacae,
Proteus mirabilis) or sample type (Table 4).
Discussion
The 3rd and 4th generation cephalosporins are often re-
served for severe infections [12] but resistance to these
drugs has been strikingly rapid worldwide [4]. Conse-
quently, therapeutic options for the infections caused by
the ESBL producers are becoming increasingly limited
and; if available, expensive for low and middle income
countries. The study revealed a slight female preponder-
ance for ESBL-producing Enterobacteriaceae among the
patients though gender was not statistically significant
(p = 0.089) as a factor. Kiratisin et al., [13] also revealed
a female preponderance.
Urine samples constituted the greatest number of clin-
ical samples in this study. According to Wilson and Gaido
[14], urinary tract infections constitute the commonest
bacterial infections and urine samples account for a sig-
nificant percentage of samples in clinical microbiology la-
boratories worldwide. Most Enterobacteriaceae isolates
were E. coli. Wilson and Gaido [14] indicates that E. coli is
the most frequent cause of urinary tract infections and this
could probably explain the high prevalence of E. coli iso-
lates in our study. Similarly, studies in Tanzania [15] indi-
cate that E. coli and Klebsiella pneumoniae are the most
prevalent Enterobacteriaceae species in clinical samples.
Furthermore, Maina et al., [16] in a study in Kenya re-
ported higher prevalence for E. coli (53.8 %). Similar find-
ings were reported in Bahrain [17].
In our study, the highest numbers of ESBL-producing
isolates were from gynaecological and surgical wards.
Many studies associate ESBL-producing Enterobacteria-
ceae with surgical wards. Studies by Seni et al., [9] show
that most isolates from surgical wards are ESBL-producers.
Prolonged hospital stay; inappropriate therapy; use of in-
dwelling catheters, endotracheal/nasogastric tubes and se-
vere illnesses are all possible drivers of their dissemination.
Significantly, there is also movement of health workers
between wards in the hospital and can migrate ESBL-
producers from ward to ward leading to dissemination
throughout the hospital.
The prevalence of ESBL producers among Enterobacte-
riaceae (62 %) was quite high compared to that reported
by Moyo et al., [15] in Tanzania (45.2 %). This wide vari-
ation in prevalence is probably due to differences in types
of samples analysed and the extent of antibiotic use in the
various wards. The present study reveals that K. pneumo-
niae and E. coli are major ESBL producers. Moyo et al.,
[15] showed 51.5 % and 39.1 % ESBL positivity among
Klebsiella spp and E. coli respectively. On the other hand,
Table 5 Mean zone of clearance (± SD) of Enterobacteriaceae
segregated by ESBL phenotype
Antibiotic ESBL Non-ESBL P value
Ceftazidime 10.1 ± 6.2 18.1 ± 7 0.000
Cefotaxime 13.4 ± 8.3 21.6 ± 8.3 0.000
Ceftazidime-Clavulanic acid 22.3 ± 6 20.7 ± 6.8 0.198
Cefotaxime-Clavulanic acid 25.1 ± 6.6 22.3 ± 8.3 0.051
The zones of clearance of ceftazidime and cefotaxime were statistically
significantly associated with ESBL phenotype (Independent samples t-test)
Table 6 Susceptibility pattern of Enterobacteriaceae to ceftazidime and cefotaxime
Ceftazidime (%) Cefotaxime (%)
Resistant Intermediate Susceptible Resistant Intermediate Susceptible
E. coli 41 (66.1) 7 (11.3) 14 (22.6) 32 (51.6) 9 (14.5) 21 (33.9)
E. cloacae 4 (100) 0 (0) 0 (0) 3 (75) 0 (0) 1 (25)
K. pneumoniae 27 (81.8) 1 (3) 5 (15.2) 21 (63.6) 3 (9.1) 9 (27.3)
Proteus mirabilis 12 (75) 3 (18.8) 1 (6.3) 10 (62.5) 1 (6.3) 5 (31.2)
% 73.0 9.6 17.4 57.5 11.3 31.3
There was a higher percentage of Enterobacteriaceae isolates showing resistance to ceftazidime than to cefotaxime. The interpretative criteria used was based on
CLSI M100-S20 (2010) [11] where for ceftazidime (Resistant ≤17 mm; Intermediate 18-20 mm; Susceptible ≥ 21 mm) and for cefotaxime (Resistant ≤22 mm; Intermediate
23-25 mm; Susceptible ≥ 26 mm)
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Seni et al., [9] reported that 79.2 % and 92.3 % of E. coli
and K. pneumoniae isolates are ESBL producers; further
evidence that these two organisms account for most ESBL
producers in the region. Our study showed a higher resist-
ance to ceftazidime than to cefotaxime. On the other hand,
Maina et al., [16] reported 21.2 % resistance to ceftazidime
and 65.4 % resistance to cefotaxime. The differences seen
in this study could be due to regional differences and the
type of samples collected.
Conclusions
This study has demonstrated high prevalence of ESBL-
producing Enterobacteriaceae in Mulago Hospital. The
spread of these organisms reduces the antibiotic alterna-
tives for the treatment of infections by these pathogens to
mainly carbapenems; which are often reserved for life-
threatening infections. The study underscores the need for
routine detection and reporting of ESBL-producers in
Ugandan medical facilities so that measures are taken to
avoid their uncontrolled spread and possible therapeutic
failures. Clinicians need to be rational and judicious in use
of antibiotics. An antibiotic use policy is also imperative to
limit the dissemination of these organisms.
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